University College London (UCL) Researcher Advances Knowledge in Disease Progression ("Paradoxical" Cerebral Volume Changes in Anti-Amyloid Immunotherapy Trials).

A recent study conducted at University College London (UCL) examined the impact of anti-amyloid immunotherapy on disease progression in Alzheimer's patients. The research found that treatment with lecanemab resulted in greater whole brain volume loss, potentially due to reduced amyloid plaques and inflammation, but did not lead to neuronal loss. The study highlights the complex relationship between volume changes, biomarkers, and clinical outcomes in Alzheimer's disease. For more information, the full article can be accessed at https://doi.org/10.1002/alz.091961. [Extracted from the article]